Nautilus Biotechnology, Inc. NAUT

NAUT Company Overview

Nautilus Biotechnology, Inc. is a U.S.-based life sciences and biotechnology company focused on developing a next-generation proteomics platform designed to analyze and quantify proteins at large scale and high sensitivity. The company operates primarily within the proteomics, bioanalytics, and biotechnology tools industries, with an emphasis on enabling comprehensive analysis of the human proteome for research, translational medicine, and drug discovery applications. Nautilus seeks to address limitations in existing proteomics technologies by combining protein identification, quantification, and characterization capabilities into a scalable platform intended for broad research use.

The company’s primary business objective is the commercialization of its proteome analysis system, which integrates proprietary chemistry, software, machine learning, and single-molecule detection technologies. Revenue generation has historically been limited because the company has remained in the development and pre-commercial stage, relying largely on capital markets and strategic collaborations. Nautilus has positioned itself as a technology innovator within proteomics by targeting higher throughput and deeper protein analysis than conventional mass spectrometry workflows. The company was founded in 2016 by researchers and entrepreneurs including Sujal Patel and Professor Leroy Hood, and later became publicly traded through a merger with a special purpose acquisition company in 2021.